3billion Announces ‘AI Drug Discovery Innovation’ at Future Healthcare Trend Conference

On September 2nd, the <2025 Future Healthcare Trend Conference>, hosted by Medigate News, was held at COEX, Seoul. This conference was organized to share the latest trends in the healthcare industry and actual application cases of AI technology, with leading companies in the industry such as AWS, Microsoft, VUNO, Daewoong Pharmaceutical, and Coreline Soft participating.

3billion presented on the topic of ‘Rare Disease Diagnosis, Data, and AI Drug Discovery Innovation’ in the last session, ‘Digital Healthcare and Pharmaceutical/Bio Collaboration: Challenging Beyond Diagnosis to Treatment.’

Changwon Keum, CEO of 3billion, mentioned Google’s AlphaFold, AlphaMissense, and AlphaGenome cases in his presentation, explaining how rapidly AI is evolving in the fields of life science and genomics research. He also emphasized that in this global technological competition, the key to differentiation ultimately lies in ‘data.’

3billion has accumulated over 80,000 cases of rare disease patient genomic and clinical data through its whole genome sequencing (WGS) and exome sequencing (WES)-based genetic diagnostic testing services. Based on this real patient data, 3billion has advanced its proprietary AI genetic variant interpretation model, and is currently expanding this to building an AI drug discovery platform for drug candidate discovery.

This presentation was an opportunity to show that 3billion is not merely a rare disease diagnostic company, but is leaping forward as an innovative medical AI company that connects patient diagnosis to treatment. Furthermore, by sharing the stage with global IT, pharmaceutical, and bio companies, 3billion reaffirmed its status as a leading company in the domestic rare disease diagnosis field.

3billion plans to continue responding to the needs of patients and the medical field, growing into a company that leads the paradigm shift in rare disease diagnosis and treatment.